Literature DB >> 21692673

Management of viral infections in solid organ transplant recipients.

Raymund R Razonable1.   

Abstract

Management of viral infections after transplantation involves antiviral drug therapy (if available) and reduction in immunosuppression, which allows for development of pathogen-specific immunity to the offending virus. Prevention of viral infections is of the utmost importance, and this may be accomplished through vaccination, antiviral strategies and infection control measures. This article discusses the current management of selected viral pathogens that cause clinical illness in solid organ transplant recipients. The benefits and toxicities of antiviral therapies are discussed in the context of prevention and treatment of various viral diseases. The emerging issue of antiviral resistance is emphasized for cytomegalovirus, recurrent hepatitis B and influenza, while the importance of immunominimization is discussed in the management of BK nephropathy and virus-associated malignancies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21692673     DOI: 10.1586/eri.11.43

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  6 in total

1.  Antiviral T cell response triggers cytomegalovirus hepatitis in mice.

Authors:  Devon Livingston-Rosanoff; Lisa P Daley-Bauer; AnaPatricia Garcia; A Louise McCormick; Jing Huang; Edward S Mocarski
Journal:  J Virol       Date:  2012-09-19       Impact factor: 5.103

2.  How should I manage immunosuppression in a kidney transplant patient with COVID-19? An ERA-EDTA DESCARTES expert opinion.

Authors:  Umberto Maggiore; Daniel Abramowicz; Marta Crespo; Christophe Mariat; Geir Mjoen; Licia Peruzzi; Mehmet Sükrü Sever; Gabriel C Oniscu; Luuk Hilbrands; Bruno Watschinger
Journal:  Nephrol Dial Transplant       Date:  2020-06-01       Impact factor: 5.992

3.  Metagenomic Next-Generation Sequencing for Identification and Quantitation of Transplant-Related DNA Viruses.

Authors:  Meredith L Carpenter; Susanna K Tan; Thomas Watson; Rowena Bacher; Vaishnavi Nagesh; Alain Watts; Gordon Bentley; Jenna Weber; ChunHong Huang; Malaya K Sahoo; Armin Hinterwirth; Thuy Doan; Theodore Carter; Queeny Dong; Stéphane Gourguechon; Eric Harness; Sean Kermes; Srihari Radhakrishnan; Gongbo Wang; Alejandro Quiroz-Zárate; Jesus Ching; Benjamin A Pinsky
Journal:  J Clin Microbiol       Date:  2019-11-22       Impact factor: 5.948

4.  [Management of immunosuppressive therapy in kidney transplant recipients with COVID19. A multicentre national study derived form the S.E.N. COVID registry.]

Authors:  María O López-Oliva; Isabel Pérez-Flores; María Molina; Mª José Aladrén; Hernando Trujillo; Dolores Redondo-Pachón; Verónica López; Carme Facundo; Florentino Villanego; Marisa Rodríguez; Mª Carmen Ruiz; Paula Antón; Alba Rivas-Oural; Sheila Cabello; José Portolés; Lourdes de la Vara; Guadalupe Tabernero; Rosalía Valero; Cristina Galeano; Esperanza Moral; Ana Ventura; Armando Coca; Miguel Ángel Muñoz; Román Hernández-Gallego; Amir Shabaka; Gabriel Ledesma; Patricia Martínez; Mª Ángeles Rodríguez; Lourdes Pérez Tamajón; Leónidas Cruzado; J Emilio Sánchez; Carlos Jiménez
Journal:  Nefrologia       Date:  2022-04-30       Impact factor: 2.033

5.  [Infections in immunocompromised patients (II). The transplanted patient].

Authors:  A Ramos Martínez; I Pintos Pascual; E Múñez Rubio
Journal:  Medicine (Madr)       Date:  2018-05-08

6.  Immunosuppression minimization in kidney transplant recipients hospitalized for COVID-19.

Authors:  Paula Anton Pampols; Hernando Trujillo; Edoardo Melilli; Blanca Urban; Justo Sandino; Alexandre Favá; Eduardo Gutierrez; Oriol Bestard; Esther Mancebo; Angel Sevillano; Josep M Cruzado; Enrique Morales
Journal:  Clin Kidney J       Date:  2021-01-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.